Is disease flare a problem?

When given for the first time to previously untreated patients with advanced prostate cancer, luteinizing hormone-releasing hormone (LHRH) analogs induce a transient rise in pituitary luteinizing hormone levels. As a consequence of this increase of LH, there is, within the first 2 to 3 days, a surge of testosterone, which can cause an exacerbation of the… CONTINUE READING